Adults with cystic fibrosis experience higher pain prevalence and severity compared to healthy controls, with significant unmet needs in pain management. New study highlights critical gaps in care.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring (fibrosis) of lung tissue, ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public ...

When cystic fibrosis hits your lungs hard, hit back. Everything you need to know about getting your lungs back into shape is ...

Piper Sandler made a slight adjustment to the price target of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), bringing it down to $533 from the previous target of $535, while maintaining an ...

A Wicklow mother is among a concerned group of parents who are calling for individual trials of the modulator therapies for ...

The Milligans were sent off on their trip by Georgia Strait Towing, which helps volunteer and fundraise for Help Fill a Dream ...

Its Respiratory Advisory Committee has recommended funding with high priority for children aged two to five years. The medicine is currently only funded for ages six and up Cystic Fibrosis NZ CEO Lisa ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Patients treated with Trikafta or other cystic fibrosis therapies can also still have declining lung function, or may cut ...